U.S. Alzheimer's Disease Medication Market

 

Regular Price: USD 4,950

Special Price USD 3,465

30% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 3,465

PAY BY INVOICE

Be the first to review this product

This research service provides an indepth analysis of factors affecting the growth of the U.S. Alzheimer's disease medication market over the period 2006-2016. Following an introduction to the market, which includes segmentation, patient forecasts, and market trends, readers are presented with a detailed examination of therapeutic candidates in Alzheimer's pipeline. Finally, revenue forecasts and market share analyses are presented for existing therapies as well as three new-mechanism drugs with potential to reach the market within the forecast period.

Table of Contents

U.S. Alzheimer's Disease Medication Market, Executive SummaryU.S. Alzheimer's Disease Medication MarketIntroductionU.S. Alzheimer's Disease Medication Market, Market IntroductionResearch Scope and MethodologyScope and SegmentationResearch MethodologyInformation Update Regarding Eli Lilly’s Discontinuation of semagacestat Clinical TrialsDisease Overview and Patient ForecastsDisease OverviewDiseases Causes and Risk FactorsDiagnosisPatient ForecastsMarket TrendsMarket Engineering MeasurementsIndustry Challenges and StrategiesMarket DriversU.S. Alzheimer's Disease Medication Market, Product and Pipeline AnalysisApproved Product OverviewIntroductionCholinesterase InhibitorsNMDA Receptor AntagonistsPipeline Analysis by Mechanism of ActionCholinesterase InhibitorsNMDA Receptor AntagonistsAmyloid Plaque InhibitorsNicotinic Receptor AgonistsOther New Mechanism DrugsU.S. Alzheimer's Disease Medication Market, Market AnalysisRevenue ForecastsTotal Alzheimer's Disease Medication MarketCholinesterase InhibitorsNMDA Receptor AntagonistsPotential New Market EntrantsCompetitive OverviewCompetitive StructureMarket Share AnalysisMarket Share AnalysisU.S. Alzheimer's Disease Medication Market, AppendixDecision Support DatabasesTotal PopulationPopulation Above 65 YearsPercent of Population Above 65 YearsAlzheimer's Disease PopulationAlzheimer's Disease DeathsTotal Cases of Dementia




Related Research

Release Date : 18-Sep-17

Region : North America

Release Date : 18-Sep-17

Region : North America

Release Date : 18-Sep-17

Region : North America

Release Date : 15-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.